These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 37871757)

  • 1. Targeting residual inflammatory risk: The next frontier for atherosclerosis treatment and prevention.
    Ridker PM
    Vascul Pharmacol; 2023 Dec; 153():107238. PubMed ID: 37871757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inflammation and Cholesterol as Predictors of Cardiovascular Events Among 13 970 Contemporary High-Risk Patients With Statin Intolerance.
    Ridker PM; Lei L; Louie MJ; Haddad T; Nicholls SJ; Lincoff AM; Libby P; Nissen SE;
    Circulation; 2024 Jan; 149(1):28-35. PubMed ID: 37929602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials.
    Ridker PM; Bhatt DL; Pradhan AD; Glynn RJ; MacFadyen JG; Nissen SE;
    Lancet; 2023 Apr; 401(10384):1293-1301. PubMed ID: 36893777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-Dose Colchicine for Secondary Prevention of Coronary Artery Disease: JACC Review Topic of the Week.
    Nelson K; Fuster V; Ridker PM
    J Am Coll Cardiol; 2023 Aug; 82(7):648-660. PubMed ID: 37558377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. From C-Reactive Protein to Interleukin-6 to Interleukin-1: Moving Upstream To Identify Novel Targets for Atheroprotection.
    Ridker PM
    Circ Res; 2016 Jan; 118(1):145-56. PubMed ID: 26837745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Why Colchicine Should Be Considered for Secondary Prevention of Atherosclerosis: An Overview.
    Nidorf SM; Thompson PL
    Clin Ther; 2019 Jan; 41(1):41-48. PubMed ID: 30591286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease--a perspective.
    Kones R
    Drug Des Devel Ther; 2010 Dec; 4():383-413. PubMed ID: 21267417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inflammation, C-reactive protein, and atherothrombosis.
    Ridker PM; Silvertown JD
    J Periodontol; 2008 Aug; 79(8 Suppl):1544-51. PubMed ID: 18673009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of interleukin-6, C-reactive protein, and low-density lipoprotein cholesterol as biomarkers of residual risk in contemporary practice: secondary analyses from the Cardiovascular Inflammation Reduction Trial.
    Ridker PM; MacFadyen JG; Glynn RJ; Bradwin G; Hasan AA; Rifai N
    Eur Heart J; 2020 Aug; 41(31):2952-2961. PubMed ID: 32221587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Residual Inflammatory Risk on Treatment With PCSK9 Inhibition and Statin Therapy.
    Pradhan AD; Aday AW; Rose LM; Ridker PM
    Circulation; 2018 Jul; 138(2):141-149. PubMed ID: 29716940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Canadian Study of Arterial Inflammation in Patients with Diabetes and Recent Vascular Events, Evaluation of Colchicine Effectiveness (CADENCE): protocol for a randomised, double-blind, placebo-controlled trial.
    Boczar KE; Shin S; deKemp RA; Dowlatshahi D; Tavoosi A; Wiefels C; Liu P; Lochnan H; MacPherson PA; Chong AY; Torres C; Leung E; Tawakol A; Ahmadi A; Garrard L; Lefebvre C; Kelly C; MacPhee P; Tilokee E; Raggi P; Wells GA; Beanlands R
    BMJ Open; 2023 Nov; 13(11):e074463. PubMed ID: 37949621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reducing residual cardiovascular risk in Europe: Therapeutic implications of European medicines agency approval of icosapent ethyl/eicosapentaenoic acid.
    Chapman MJ; Zamorano JL; Parhofer KG
    Pharmacol Ther; 2022 Sep; 237():108172. PubMed ID: 35304222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High Sensitivity C-reactive Protein (hsCRP) and its Implications in Cardiovascular Outcomes.
    Denegri A; Boriani G
    Curr Pharm Des; 2021; 27(2):263-275. PubMed ID: 32679014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Moving beyond JUPITER: will inhibiting inflammation reduce vascular event rates?
    Ridker PM
    Curr Atheroscler Rep; 2013 Jan; 15(1):295. PubMed ID: 23225175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Statin/Ezetimibe for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Asian Populations: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Bhagavathula AS; Aldhaleei WA; Al Matrooshi NO; Rahmani J
    Clin Drug Investig; 2020 Sep; 40(9):809-826. PubMed ID: 32671595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inflammation and beyond: new directions and emerging drugs for treating atherosclerosis.
    Bertrand MJ; Tardif JC
    Expert Opin Emerg Drugs; 2017 Mar; 22(1):1-26. PubMed ID: 27927063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
    Mora S; Ridker PM
    Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. From CANTOS to CIRT to COLCOT to Clinic: Will All Atherosclerosis Patients Soon Be Treated With Combination Lipid-Lowering and Inflammation-Inhibiting Agents?
    Ridker PM
    Circulation; 2020 Mar; 141(10):787-789. PubMed ID: 32150469
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial.
    Giugliano RP; Keech A; Murphy SA; Huber K; Tokgozoglu SL; Lewis BS; Ferreira J; Pineda AL; Somaratne R; Sever PS; Pedersen TR; Sabatine MS
    JAMA Cardiol; 2017 Dec; 2(12):1385-1391. PubMed ID: 29117276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of PCSK9 Inhibition With Evolocumab in Reducing Cardiovascular Events in Patients With Metabolic Syndrome Receiving Statin Therapy: Secondary Analysis From the FOURIER Randomized Clinical Trial.
    Deedwania P; Murphy SA; Scheen A; Badariene J; Pineda AL; Honarpour N; Keech AC; Sever PS; Pedersen TR; Sabatine MS; Giugliano RP
    JAMA Cardiol; 2021 Feb; 6(2):139-147. PubMed ID: 32785614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.